title: [Pulmonary sarcoidosis associated with pegylated interferon in the treatment of chronic hepatitis C].
abstract: Treatment with pegylated interferon is usually used in active chronic hepatitis C in association with ribavirin. The adverse effects of interferon include influenza-like syndrome and mild respiratory manifestations, which are highly frequent. Among the immunomodulatory effects is the possibility of inducing or exacerbating autoimmune phenomena such as cutaneous or systemic sarcoidosis. We present a new case of pulmonary sarcoidosis induced by pegylated interferon in a 35 year-old woman with chronic hepatitis C who developed respiratory symptoms 4 months after starting therapy with pegylated interferon associated with ribavirin. Radiological images showed a micronodular pattern in both pulmonary fields together with hilar and mediastinal adenopathies. Transbronchial biopsy confirmed the presence of sarcoidal granulomas. After the diagnosis of pulmonary sarcoidosis, antiviral therapy was suspended with subsequent resolution of the clinical symptoms.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Costa del Sol, Marbella, Málaga, Spain. estherillaua@hotmail.com
authors.forename: E
authors.initials: E
authors.lastname: Ubiña-Aznar
authors.forename: N
authors.initials: N
authors.lastname: Fernández-Moreno
authors.forename: R
authors.initials: R
authors.lastname: Rivera-Irigoín
authors.forename: J M
authors.initials: JM
authors.lastname: Navarro-Jarabo
authors.forename: G
authors.initials: G
authors.lastname: García-Fernández
authors.forename: A
authors.initials: A
authors.lastname: Pérez-Aisa
authors.forename: F
authors.initials: F
authors.lastname: Vera-Rivero
authors.forename: F
authors.initials: F
authors.lastname: Fernández-Pérez
authors.forename: P
authors.initials: P
authors.lastname: Moreno-Mejías
authors.forename: I
authors.initials: I
authors.lastname: Méndez-Sánchez
authors.forename: C
authors.initials: C
authors.lastname: de Sola-Earle
authors.forename: A
authors.initials: A
authors.lastname: Sánchez-Cantos
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced* / Q000000981:diagnostic imaging; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D014057:Tomography, X-Ray Computed
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012254:Ribavirin